(MENAFN - The Peninsula) Weill Cornell Medical College in Qatar (WCMC-Q) has launched a new programme of interactive learning sessions to help practising healthcare professionals identify key challenges of meeting a variety of healthcare needs. It also aims to discuss how this impacts their ability to manage patients, and to explore the benefits of a multidisciplinary approach to patient care. The Grand Rounds, developed by WCMC-Q's Division of Continuing Professional Development, features presentations by expert speakers that aim to engage healthcare professionals in the community to enhance their knowledge of the latest developments in medical technology, research and best practice. The latest Grand Round brought Dr Ronald G Crystal, one of the world's foremost researchers in genetic medicine, to Doha to discuss the cutting-edge research being carried out in his laboratory in New York. Addressing an audience of approximately 100 medical professionals, students and faculty members convened at WCMC-Q, Dr Crystal, Professor and Chairman of the Department of Genetic Medicine at Weill Cornell Medical College in New York, explained how researchers have been able to use viruses as vehicles to insert new genetic material into living cells. It is hoped that the technology, which is still in the early stages … Continue reading →

Background We previously showed that consolidation therapy with thalidomide and prednisolone improved progression-free and overall survival in patients with multiple myeloma who had undergone autologous stem-cell transplantation. We aimed to assess whether these survival advantages were durable at 5 years. The ALLG MM6 trial was a multicentre, open-label, randomised phase 3 trial done between Jan 13, 2002, and March 15, 2005, at 29 sites in Australia and New Zealand. Patients with newly diagnosed multiple myeloma were randomly assigned (1:1), via computer-generated randomisation charts, to receive indefinite prednisolone maintenance alone (control group) or in combination with 12 months of thalidomide consolidation (thalidomide group) after autologous stem-cell transplantation. Randomisation was stratified by treating centre and pre-transplantation concentrations of 2 microglobulin. Patients and treating physicians were not masked to treatment allocation. Primary endpoints were progression-free survival and overall survival. Analysis was by intention to treat. Secondary endpoints were overall response to salvage therapy, incidence of second primary malignancy incidence, and cost-effectiveness. This trial is registered with the Australian and New Zealand Clinical Trials Registry, number ACTRN12607000382471. We randomly assigned 269 patients to the thalidomide (n=114) or control group (n=129). After a median follow-up of 54 years (IQR 3172), estimated 5-year progression-free survival was … Continue reading →

Latest Hair Loss Research : Stem Cell Therapy and Stem Cell Nutrition for Hair Loss For More Details Like Us : https://www.facebook.com/SuperStemCellNutrition. By: Palu Sot … Continue reading →

A decade ago, a dream team of researchers from Pittsburgh to South Korea claimed a medical invention that promised to reshape a culture war. The scientists said they custom-designed stem cells from cloned human embryos. The scientific breakthrough was celebrated around the globe. Then the bottom fell out. A scandal erupted over fabricated data, and University of Pittsburgh biologist Gerald Schatten was forced to pull back the findings. Critics cast the 2004 discovery as a farce, a high-profile fraud that forced the journal Science into a rare retraction in January 2006. Eight years later, the push to use stem cells as a medical treatment continues, but scholars balk at the suggestion that anyone is trying to make genetically identical individuals. We're not here to clone human beings, for gosh sakes, said John Gearhart, a stem cell researcher and University of Pennsylvania professor in regenerative medicine. Instead, he said, scholars are working to manipulate stem cells to produce heart cells for cardiac patients, brain cells for neurological patients and other custom transplants that could match a person's genetic makeup. Schatten's work continues at the Magee-Womens Research Institute at Pitt, where university officials cleared him of scientific misconduct, and he remains a … Continue reading →